NCT06630260View on ClinicalTrials.gov

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2030

Conditions
Glioblastoma Multiforme (GBM)Glioblastoma Multiform (Grade IV Astrocytoma)Diffuse Hemispheric Glioma, H3 G34-MutantMalignant Primary Gliomas
Interventions
DRUG

Avutometinib

Supplied as 0.8mg capsules.

DRUG

Defactinib

Supplied as 200mg tablets.

DRUG

Temozolomide

Temozolomide will be supplied as 5, 20, 100, 140, 180 or 250 mg hard capsules.

Trial Locations (3)

CB2 0QQ

RECRUITING

Cambridge University Hospitals, Cambridge

SM2 5PT

RECRUITING

The Royal Marsden Hospital - Drug Development Unit, Sutton

NOT_YET_RECRUITING

The Royal Marsden Hospital - Neuro-Oncology Unit, Sutton

Sponsors
All Listed Sponsors
collaborator

Minderoo Foundation

UNKNOWN

collaborator

Verastem, Inc.

INDUSTRY

collaborator

Royal Marsden NHS Foundation Trust

OTHER

collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

collaborator

Cancer Research UK

OTHER

collaborator

University of Cambridge

OTHER

lead

Institute of Cancer Research, United Kingdom

OTHER